Cargando…

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma

SIMPLE SUMMARY: Immunotherapy leads to durable responses in a proportion of patients with advanced melanoma. Combination immunotherapy is more efficacious than single-agent immunotherapy, yet it is associated with significant toxicity. Currently there are no robust biomarkers to guide first-line imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shklovskaya, Elena, Lee, Jenny H, Lim, Su Yin, Stewart, Ashleigh, Pedersen, Bernadette, Ferguson, Peter, Saw, Robyn PM, Thompson, John F, Shivalingam, Brindha, Carlino, Matteo S, Scolyer, Richard A, Menzies, Alexander M, Long, Georgina V, Kefford, Richard F, Rizos, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696726/ https://www.ncbi.nlm.nih.gov/pubmed/33202676 http://dx.doi.org/10.3390/cancers12113374

Ejemplares similares

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
por: Lee, Jenny H., et al.
Publicado: (2020)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Interferon Signaling Is Frequently Downregulated in Melanoma
por: Alavi, Sara, et al.
Publicado: (2018)

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2020)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
por: Lim, Su Yin, et al.
Publicado: (2017)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
por: Irvine, Mal, et al.
Publicado: (2018)

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma
por: Diefenbach, Russell J., et al.
Publicado: (2019)

MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
por: Shklovskaya, Elena, et al.
Publicado: (2021)

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
por: Conway, Jordan W, et al.
Publicado: (2022)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
por: Lee, J H, et al.
Publicado: (2019)

Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling
por: Chien, Andy J., et al.
Publicado: (2014)

Melanoma Cell State-Specific Responses to TNFα
por: Lim, Su Yin, et al.
Publicado: (2021)

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
por: Mao, Yizhe, et al.
Publicado: (2023)

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
por: Park, John J., et al.
Publicado: (2022)

Liquid biomarkers in melanoma: detection and discovery
por: Lim, Su Yin, et al.
Publicado: (2018)

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma
por: Menzies, Alexander M., et al.
Publicado: (2014)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors
por: Lezcano, Cecilia, et al.
Publicado: (2014)

SERS characterization of colorectal cancer cell surface markers upon anti‐EGFR treatment
por: Lyu, Nana, et al.
Publicado: (2022)

Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition
por: Park, John J., et al.
Publicado: (2021)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
por: Quek, Camelia, et al.
Publicado: (2021)

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas
por: Quek, Camelia, et al.
Publicado: (2019)

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
por: Carlino, Matteo S, et al.
Publicado: (2016)

Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients
por: Du Four, Stephanie, et al.
Publicado: (2014)

The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence
por: Rabbie, Roy, et al.
Publicado: (2020)

Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
por: Shklovskaya, Elena, et al.
Publicado: (2020)

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
por: Lee, Hansol, et al.
Publicado: (2021)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

p16(INK4a)-induced senescence is disabled by melanoma-associated mutations
por: Haferkamp, Sebastian, et al.
Publicado: (2008)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Oncogenic B-RAF(V600E) signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion
por: Boyd, Suzanah C., et al.
Publicado: (2012)

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)

Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome
por: Attrill, Grace H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lndev42fricdca1edntshajjb9